77 results
8-K
EX-99.1
DNLI
Denali Therapeutics Inc
27 Feb 24
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
8:07am
the collaboration agreements.
Total research and development expenses were $107.8 million and $423.9 million for the quarter and year ended December … external research and development expenses due to the timing of significant external research and manufacturing related activities period over period
8-K
DNLI
Denali Therapeutics Inc
27 Feb 24
Denali Therapeutics Announces $500 million Private Placement Equity Financing
8:03am
the financing are expected to be used to support Denali’s ongoing research and development activities, the acceleration and expansion of its proprietary BBB
8-K
EX-99.1
jr6h0eb 8d3k
27 Feb 24
Denali Therapeutics Announces $500 million Private Placement Equity Financing
8:03am
8-K
EX-99.1
upwtz9ao
7 Nov 23
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
4:04pm
8-K
EX-99.1
3zfml9gorviulqv68ed9
8 Aug 23
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
4:04pm
8-K
EX-99.1
mtv3 8573
8 May 23
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
4:03pm
8-K
EX-99.1
yvn320dlu4mte5d
3 Nov 22
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
4:05pm
424B5
9eeqm6pe18t
20 Oct 22
Prospectus supplement for primary offering
4:57pm
8-K
EX-99.3
au1zjzpv3xef9k7d4fxc
18 Oct 22
Denali Therapeutics Announces Proposed Offering of Common Stock
5:09pm
424B5
6iri5hg8m
18 Oct 22
Prospectus supplement for primary offering
5:08pm
8-K
EX-99.1
zcy5 tt5iginq1f51
8 Aug 22
Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
4:03pm